A systematic review on disease-drug-drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling.

Laura M de Jong Sylvia D KlompNicoline TreijtelRobert Rissmann Jesse Joachim Swen Martijn L Manson

Published in: British journal of clinical pharmacology (2022)

This systematic review reinforces that the risk for DDDI by immunomodulating drugs is target- and disease-specific. Drug labelling information designates the greatest DDDI risk to mAbs that neutralize the effects of IL-6, Tumor Necrosis Factor alfa (TNF-α) and interleukin-1 bèta (IL-1β) in diseases with systemic inflammation.

Keyphrases

systematic review
risk assessment
rheumatoid arthritis
drug induced
adverse drug
meta analyses
emergency department
healthcare
randomized controlled trial
heavy metals
human health
climate change
health information
replacement therapy